Latest News on OSUR

Financial News Based On Company


Advertisement
Advertisement

Earnings Update: Here's Why Analysts Just Lifted Their OraSure Technologies, Inc. (NASDAQ:OSUR) Price Target To US$5.50

https://simplywall.st/stocks/us/healthcare/nasdaq-osur/orasure-technologies/news/earnings-update-heres-why-analysts-just-lifted-their-orasure
OraSure Technologies, Inc. (NASDAQ:OSUR) saw its shares fall 4.3% despite a positive third-quarter earnings report where revenues met predictions and statutory losses were smaller than expected. Analysts have since updated their forecasts, maintaining revenue estimates but significantly reducing loss per share projections for 2027, which led to a 16% increase in the average price target to US$5.50. The company is also expected to accelerate revenue growth, outperforming the broader industry.

OraSure Pushes Operating Cash Flow Breakeven to Second Half of 2027

https://www.tokenpost.com/news/business/53726
OraSure Technologies has revised its expectation for reaching operating cash flow breakeven, now projecting it for the second half of 2027 instead of early 2027. The company forecasts Q4 2026 revenue between $30 million and $32 million, with gross margins anticipated to be similar to or slightly below the third-quarter level. In Q3, OraSure expanded gross margins, reduced operating expenses, and launched new products like its Ebola 2.0 test and Colli-Pee Dx.

Diagnostics company joins global coalition to boost sickle cell care

https://sicklecellanemianews.com/news/diagnostics-company-joins-global-coalition-boost-sickle-cell-care/
Orasure Technologies has joined the World Coalition on Sickle Cell Disease, an international public-private partnership aimed at improving care for individuals affected by sickle cell disease globally. The company will contribute its expertise in diagnostics, particularly point-of-care tests, to help strengthen the connection between diagnosis and treatment. This collaboration seeks to facilitate earlier and more accurate diagnoses, especially in regions with limited medical access, and to ensure clear pathways to appropriate care and ongoing treatment.

OraSure delays break-even timing, eyes new global growth opportunities

https://www.wfmz.com/business/orasure-delays-break-even-timing-eyes-new-global-growth-opportunities/article_303a4226-08e4-4c1c-9d4c-eade5f97e76a.html
OraSure Technologies announced a delay in achieving operational cash flow break-even status until the second half of 2027, citing shifting growth opportunities. Despite this, the Bethlehem-based medtech company reported revenue growth in its third quarter 2026 financial results and is focusing on expanding its HIV and Ebola testing products globally, particularly in Africa. The company's stock was down slightly after the announcement but remains up over 43% year-to-date.

OraSure Technologies Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:ecf6e7721094b:0-orasure-technologies-q3-earnings-call-highlights/
OraSure Technologies reported a 14% year-over-year revenue increase in Q3 2026, reaching $30.9 million, but adjusted its operating cash flow breakeven target to the second half of 2027 due to shifting product opportunities. The company saw growth in diagnostic products and sample management solutions, with improved gross margins and reduced operating expenses. OraSure also provided a Q4 revenue forecast of $30 million to $32 million and discussed developments in its Ebola rapid test and Colli-Pee Dx urine collection kit, while working on a new regulatory path for its InteliQuick CT/NG molecular self-test.
Advertisement

OraSure Technologies Q4 Results: Sales guidance misses estimates

https://scanx.trade/stock-market-news/companies/orasure-technologies-q4-results-sales-guidance-misses-estimates/55805477
OraSure Technologies reported a 14% year-over-year revenue increase to $30.9 million for Q3 fiscal 2026, driven by diagnostic products and Sample Management Solutions. Despite strong Q3 performance and expanding gross margins, the company's full-year FY26 sales guidance of $120.427 million remains below the consensus analyst estimate of $121.304 million, indicating a cautious outlook for future revenue streams. OraSure also projected Q4 sales between $30 million and $32 million, bracketing the analyst consensus of $31.701 million.

OraSure Technologies Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63076126/orasure-technologies-q3-2026-earnings-call-transcript
OraSure Technologies reported a 14% year-over-year revenue increase to $30.9 million in Q3 2026, driven by growth in diagnostic products and strategic initiatives like local manufacturing in Africa for HIV and Ebola diagnostics. The company secured FDA Emergency Use Authorization for its OraQuick Ebola 2.0 Rapid Antigen Test and anticipates full-year 2026 revenue growth of 3.8% to 5.6%, expecting accelerated growth in 2027 while aiming for cash flow from operations break-even in the second half of 2027.

OraSure Announces Third Quarter 2026 Financial Results;

https://www.globenewswire.com/news-release/2026/11/09/3398945/11732/en/orasure-announces-third-quarter-2026-financial-results-strategic-execution-drives-double-digit-year-over-year-growth-and-margin-expansion.html
OraSure Technologies, Inc. announced its financial results for the third quarter of 2026, reporting 14% year-over-year revenue growth and a significant improvement in GAAP gross margin to 45.2%. The company highlighted the successful commercial launches and initial orders for its Colli-Pee®•Dx Urine Collection Kit and OraQuick® Ebola 2.0 Rapid Antigen Test. OraSure anticipates an acceleration of full-year revenue growth in 2027, driven by strategic execution and operational efficiencies.

Form 8K OraSure Technologies Inc For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-orasure-technologies-inc-for-9-november-93CH-4944258
This article from Investing.com announces that OraSure Technologies Inc. has filed a Form 8K for November 9. The report, published on November 9, 2026, focuses on this corporate filing, indicating a significant event for the company.

Form 8K OraSure Technologies Inc For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-orasure-technologies-inc-for-9-november-93CH-4969471
OraSure Technologies Inc. (OSUR) filed a Form 8K on November 9, 2026. This filing typically reports significant events that shareholders should know about. The article provides the basic announcement of this SEC filing.
Advertisement

OraSure Technologies (OSUR) Stock Fair Value Rises As Testing Funding Outlook Stabilizes

https://sg.finance.yahoo.com/news/orasure-technologies-osur-stock-fair-140937780.html
The fair value estimate for OraSure Technologies (OSUR) has increased from US$4.00 to US$5.50 per share, driven by renewed analyst discussion regarding stabilizing HIV and HCV testing trends and a potential inflection point in its core business. Craig Hallum initiated coverage with a Buy rating and a US$7 price target, citing potential mid-teens revenue growth after 12 quarters of declines. The report also highlights risks related to execution and funding, as the bullish thesis depends on a successful transition to sustained growth.

OSUR: Stabilizing Testing Demand Makes The Core Business Matter Again

https://simplywall.st/community/narratives/us/healthcare/nasdaq-osur/orasure-technologies/hgrc9ti2-next-generation-diagnostics-will-transform-preventive-healthcare-z09d/updates/22-analysts-have-raised-their-fair-value-estimate-for-orasure-t
Analysts have raised their fair value estimate for OraSure Technologies (OSUR) from $4.00 to $5.50, driven by expectations of improved revenue trends, stabilized funding for HIV and HCV testing, and a higher future P/E multiple. Bullish views highlight the recent quarter as a potential inflection point for the core business, projecting mid-teens revenue growth after a period of declines. Bearish concerns include the company's history of revenue declines and execution risks, as well as sensitivity to public health budget shifts.

OraSure Technologies joins global coalition to improve early diagnosis and care for sickle cell disease.

https://pluang.com/en/news-feed/orasure-technologies-gabung-koalisi-global-penyakit-sel-sabuk-akses-diagnosis
OraSure Technologies has joined the World Coalition on Sickle Cell Disease, a global public-private partnership focused on elevating sickle cell disease as a critical global health concern. OraSure will contribute its expertise in decentralized and point-of-care diagnostic testing to enhance early diagnosis, screening, and patient care pathways. This initiative aims to improve access to timely diagnosis and continuous treatment, particularly in areas with limited healthcare infrastructure, to reduce mortality and enhance patient quality of life worldwide.

OraSure Technologies (OSUR) Set to Release Earnings on Monday

https://www.marketbeat.com/instant-alerts/upcoming-orasure-technologies-osur-set-to-release-earnings-on-monday-2026-11-02/
OraSure Technologies (OSUR) is scheduled to report its Q3 2026 earnings after market close on Monday, November 9th, with analysts forecasting a loss of $0.18 per share and revenue of approximately $31 million. The stock opened at $3.94, with a market capitalization of about $271.7 million, and currently holds a consensus "Hold" rating from analysts. Recent analyst actions include upgrades from "sell" to "hold" by Wall Street Zen and Zacks Research, and a "strong-buy" rating from Craig Hallum.

OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care

https://www.globenewswire.com/news-release/2026/11/02/3392914/11732/en/orasure-technologies-joins-the-world-coalition-on-sickle-cell-disease-to-advance-access-to-earlier-diagnosis-and-care.html
OraSure Technologies has joined the World Coalition on Sickle Cell Disease, a global public-private partnership aimed at improving access to diagnosis and care for sickle cell disease. OraSure will contribute its expertise in decentralized and point-of-care testing to discussions on early diagnosis, screening, and health system readiness. The collaboration seeks to strengthen the connection between diagnosis and care, emphasizing the needs of those living with the condition.
Advertisement

OraSure Technologies, Inc. (EP3.F) Seasonal returns chart

https://au.finance.yahoo.com/quote/EP3.F/seasonality/
This article provides a seasonal returns chart for OraSure Technologies, Inc. (EP3.F), displaying the average monthly price return from 2016 to 2026. The stock's current performance is noted as 3.2400 EUR, down 6.90%, as of 6:00:02 pm GMT+1.

ORASURE TECHNOLOGIES INC. R (EP3.MU) Seasonal returns chart

https://au.finance.yahoo.com/quote/EP3.MU/seasonality/
The article for ORASURE TECHNOLOGIES INC. R (EP3.MU) on Yahoo Finance indicates that seasonality data is currently unavailable for this ticker. The page provides general market information for Australia, US, Europe, Asia, cryptocurrencies, rates, commodities, and currencies, but no specific seasonal return data for EP3.MU.

Vanguard updates its OraSure (OSUR) stake, with voting power over 430,000 shares.

https://www.stocktitan.net/sec-filings/OSUR/schedule-13g-a-orasure-technologies-inc-amended-passive-investment-di-8b4b49a433ef.html
Vanguard Capital Management reported beneficial ownership of 3,330,213 common shares, or 4.82% of OraSure Technologies Inc. (OSUR) as of September 30, 2026. The filing indicates Vanguard has sole voting power over 430,000 shares and sole dispositive power over all 3,330,213 shares. This update reflects Vanguard's passive investment disclosure through an amended SCHEDULE 13G/A filing.

OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th

https://www.manilatimes.net/2026/10/27/tmt-newswire/globenewswire/orasure-to-announce-third-quarter-2026-financial-results-and-host-earnings-call-on-november-9th/2454410/amp
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced that it will release its third-quarter 2026 financial results on Monday, November 9, 2026, after the market closes. The company will also host a conference call at 5:00 p.m. Eastern Time on the same day to discuss these results, with a webcast available on its investor relations website. OraSure specializes in diagnostic tests and sample management solutions, aiming to improve healthcare access and quality.

OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th

https://www.manilatimes.net/2026/10/27/tmt-newswire/globenewswire/orasure-to-announce-third-quarter-2026-financial-results-and-host-earnings-call-on-november-9th/2454410
OraSure Technologies, Inc. announced that it will release its third-quarter 2026 financial results on Monday, November 9, 2026, after the market closes. The company will also host a conference call at 5:00 p.m. Eastern Time on the same day to discuss these results. A webcast of the call will be available on OraSure's investor relations website.
Advertisement

OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th

https://www.globenewswire.com/news-release/2026/10/26/3388545/11732/en/orasure-to-announce-third-quarter-2026-financial-results-and-host-earnings-call-on-november-9th.html
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will report its third quarter 2026 financial results on Monday, November 9, 2026, after the market closes. The company will host a conference call to discuss these results at 5:00 p.m. Eastern Time on the same day, with a webcast available on its investor relations page. OraSure is a leader in rapid diagnostic tests and sample collection solutions, aiming to transform health through actionable insights.

OraSure Technologies (NASDAQ:OSUR) Stock Breaks Above Two Hundred Day Moving Average - Should You Sell?

https://www.marketbeat.com/instant-alerts/price-orasure-technologies-nasdaq-osur-stock-breaks-above-two-hundred-day-moving-average-should-you-sell-2026-10-24/
OraSure Technologies (NASDAQ:OSUR) saw its stock price climb above its 200-day moving average, reaching $4.18 before settling at $4.13. Despite this technical breakout, analyst sentiment remains cautious, with a consensus "Reduce" rating and a $3.00 target price. Institutional investors and hedge funds hold a significant 93.5% of the company's shares.

Craig-Hallum Initiates OraSure Technologies(OSUR.US) With Buy Rating, Announces Target Price $7

https://www.moomoo.com/news/post/1002195493/craig-hallum-initiates-orasure-technologies-osurus-with-buy-rating-announces
Craig-Hallum has initiated coverage on OraSure Technologies (OSUR.US) with a Buy rating. The firm also announced a target price of $7 for the company's stock.

OraSure Technologies, Inc. Estimates – NASDAQ:OSUR

https://www.tradingview.com/symbols/NASDAQ-OSUR/financials-estimates/
This page on TradingView provides financial estimates and data for OraSure Technologies, Inc. (NASDAQ: OSUR). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends. The platform also offers disclaimers regarding investment advice.

OraSure Technologies stock sits 26.33 percent above USD 3.00 target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orasure-technologies-stock-sits-26-33-percent-above-usd-3-00-target/70377184
OraSure Technologies (OSUR) stock is trading 26.33 percent above the USD 3.00 consensus target set by MarketBeat, despite a "Reduce" rating. The company reported USD 30.64 million in revenue and USD 6.76 million in net income for Q2 2026, marking a significant improvement from the previous quarter's loss. Investors are now looking to the Q3 2026 earnings report on November 10, 2026, to assess the stock's future performance.
Advertisement

Form 4 OraSure Technologies Inc: Steven Kyle Boyd (Director) For: 29 September By Investing.com

https://za.investing.com/news/stock-market-news/form-4-orasure-technologies-inc-steven-kyle-boyd-director-for-29-september-93CH-4510615
This article reports a Form 4 filing for OraSure Technologies Inc., detailing an insider transaction by Steven Kyle Boyd, a Director, on September 29. The filing indicates a significant event related to the company's stock, as required by the SEC for insider dealings.

Form 4 OraSure Technologies Inc: Steven Kyle Boyd (Director) For: 29 September

https://ca.investing.com/news/stock-market-news/form-4-orasure-technologies-inc-steven-kyle-boyd-director-for-29-september-93CH-4887190
This article reports a Form 4 filing for OraSure Technologies Inc., indicating a transaction by Steven Kyle Boyd, a director of the company, on September 29. The filing provides details about changes in company insider holdings.

Form 4 OraSure Technologies Inc: Steven Kyle Boyd (Director) For: 29 September

https://ng.investing.com/news/stock-market-news/form-4-orasure-technologies-inc-steven-kyle-boyd-director-for-29-september-93CH-2742429
This article reports on a Form 4 filing for OraSure Technologies Inc., specifically detailing transactions made by Director Steven Kyle Boyd on September 29th. The content is a brief announcement without further details on the nature of the transactions. It is published by Investing.com.

OraSure Technologies stock sits above its USD 3.00 consensus target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orasure-technologies-stock-sits-above-its-usd-3-00-consensus-target/70348408
OraSure Technologies (OSUR) stock closed at USD 3.61 on October 16, 2026, which is above its USD 3.00 consensus target set on October 15, 2026. The company's market capitalization is USD 249.0 million with a negative P/E ratio of -5.23. OraSure Technologies is expected to report its third-quarter earnings on November 4, 2026, with anticipated revenue of USD 31.14 million and adjusted EPS of minus USD 0.18.

OraSure Technologies stock trades above USD 3.00 consensus target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orasure-technologies-stock-trades-above-usd-3-00-consensus-target/70332734
OraSure Technologies stock is trading above its USD 3.00 consensus target, despite the target being 21.47 percent below its Nasdaq quote. The company reported improved second-quarter margins with revenue of USD 30.64 million and a GAAP gross margin of 43.50 percent. The next quarterly report is anticipated on November 4, 2026, with an estimated consensus revenue of USD 31.14 million.
Advertisement

Islet engages OraSure board. OraSure Technologies stock gains 1.80 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/islet-engages-orasure-board-orasure-technologies-stock-gains-1-80-percent/70270470
Islet Management engaged OraSure Technologies on September 17, 2026, regarding potential board changes, including one or more directors. OraSure reported second-quarter 2026 revenue of USD 30.6 million and a 43.5 percent GAAP gross margin. The company's stock gained 1.80 percent, trading at EUR 3.40 on October 8, 2026, and its next earnings report is scheduled for November 4, 2026.

OraSure Technologies stock gets fresh insider grant of 4,797 shares

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orasure-technologies-stock-gets-fresh-insider-grant-of-4-797-shares/70260072
OraSure Technologies (OSUR) saw a director, Steven Kyle Boyd, granted 4,797 restricted common shares as compensation, making his direct holdings 168,031 shares. The company's second-quarter revenue declined 1.9% year-over-year to $30.64 million, with diluted EPS at $0.09. The stock closed at $3.73 on October 7, 2026, below its 52-week high but above its low, with a market capitalization of $260.0 million.

OraSure Technologies | 4: Statement of changes in beneficial ownership of securities-Director Boyd Steven Kyle

https://www.moomoo.com/news/notice/1000528591/statement-of-changes-in-beneficial-ownership-of-securities-director-boyd
This document, a Statement of Changes in Beneficial Ownership of Securities (Form 4), details the transactions involving Director Boyd Steven Kyle's holdings in OraSure Technologies. It provides formal notification of changes in his beneficial ownership, as required by securities regulations.

Islet Management engages OraSure on board changes for OraSure Technologies stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/islet-management-engages-orasure-on-board-changes-for-orasure-technologies/70214947
Islet Management has engaged OraSure Technologies' board and management regarding stockholder value and potential board changes. This engagement follows a significantly improved second quarter for OraSure, which saw a return to GAAP profitability with $6.20 million in net income, despite a slight year-over-year revenue decrease. OraSure's stock price saw a modest increase on October 2, 2026, as investors weigh the company's improved margins and activist pressure.

A 4,797-share grant replaces cash fees for OraSure (OSUR) director Steven Kyle Boyd.

https://www.stocktitan.net/sec-filings/OSUR/form-4-orasure-technologies-inc-insider-trading-activity-a832dfa40ea3.html
OraSure Technologies director Steven Kyle Boyd acquired 4,797 common shares on September 29, 2026, at $3.88 per share. These restricted shares, which vested immediately, were issued in place of cash director fees as per Boyd's election under the company's Director Compensation Policy. Following this grant, Boyd's direct holdings in OraSure Technologies increased to 168,031 shares.
Advertisement

Investor group reports 6.40 percent stake in OraSure Technologies stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/investor-group-reports-6-40-percent-stake-in-orasure-technologies-stock/70211394
An investor group, including Islet Management and Yorkville-affiliated funds, has acquired a 6.40% stake in OraSure Technologies, prompting discussions about potential board changes and capital allocation. This comes as OraSure reported a GAAP net income in Q2 2026, though operating losses persisted and revenue growth was mixed. The disclosed stake introduces governance pressure as investors evaluate the company's financial performance.

OraSure Technologies stock falls 1.5 percent as stake emerges

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orasure-technologies-stock-falls-1-5-percent-as-stake-emerges/70181601
OraSure Technologies (OSUR) stock fell 1.5% to USD 3.93 on September 24, 2026, after a new investor group, including Islet Management and Yorkville affiliated funds, disclosed a 6.4% stake and indicated potential strategic engagement. This comes as the company reported improved Q2 2026 GAAP profit of USD 6.2 million, despite a 2% year-over-year revenue decline and a decrease in cash reserves. The activist stake and recent profit turnaround are key factors for the stock, which remains below its yearly high.

Weekly Recap: Investor group for OraSure (OSUR) and Yorkville-Islet filings

https://www.tradingview.com/news/tradingview:a1fa401236233:0-weekly-recap-investor-group-for-orasure-osur-and-yorkville-islet-filings/
An investor group formed on September 11, 2026, is reportedly pressuring OraSure Technologies, Inc. (NASDAQ: OSUR) for better strategy and capital allocation, and may nominate directors for the 2027 meeting. Yorkville affiliate YA II PN (approximately 5.7%) and Islet Management (approximately 0.7%) will coordinate filings and communications regarding this effort.

OraSure Technologies stock gains 8.13 percent on September 23

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orasure-technologies-stock-gains-8-13-percent-on-september-23/70165866
OraSure Technologies (OSUR) stock saw an 8.13 percent increase on September 23, 2026, closing at USD 3.99. This places the stock 31.2 percent below its 52-week high of USD 5.80 and 45.6 percent above its 52-week low of USD 2.74. With a market capitalization of USD 6.017 million and low trading volume, the company remains a small-cap stock.

Perspective: First-Void Urine - A New Era in Accessible STI Testing

https://www.genomeweb.com/sponsored/partner-content/gnw-dna-genotek-sti-urine-testing/
This article, titled "Perspective: First-Void Urine - A New Era in Accessible STI Testing," highlights the potential of first-void urine as a more accessible and convenient method for STI testing. It suggests that this approach could usher in a new era for improving public health by making testing easier for individuals.
Advertisement

Yorkville Advisors Pushes for Changes at OraSure Technologies with 6.4% Stake

https://www.tradingview.com/news/tradingview:9a31ac0cfc530:0-yorkville-advisors-pushes-for-changes-at-orasure-technologies-with-6-4-stake/
Yorkville Advisors and Islet Management have collectively acquired a 6.4% stake in OraSure Technologies, Inc., leading to the filing of a Schedule 13D. The group intends to engage with OraSure's board and management to enhance stockholder value, including potential director nominations at the 2027 annual meeting. Their strategy focuses on influencing strategy, capital allocation, and exploring options to boost company performance.

Investor group at OraSure Technologies (OSUR) may seek board seats and a possible sale

https://www.stocktitan.net/sec-filings/OSUR/schedule-13d-orasure-technologies-inc-major-shareholder-acquisition-5-4a080a0070d2.html
A new investor group, comprising Islet Management and Yorkville-affiliated funds, has acquired a 6.4% stake in OraSure Technologies (OSUR), believing the shares are undervalued. The group, formed on September 11, 2026, aims to enhance stockholder value, potentially by nominating directors for the 2027 annual meeting and discussing changes to capital allocation, ownership structure, or even a company sale. Islet Management also holds economic exposure to an additional 0.7% of shares through cash-settled total return swaps.

OraSure Technologies (OSUR) director reports tax withholding on vested shares

https://www.stocktitan.net/sec-filings/OSUR/form-4-orasure-technologies-inc-insider-trading-activity-6c27ee44aa61.html
OraSure Technologies director John P. Kenny reported a transaction where 5,116 shares of common stock were withheld to cover tax liabilities associated with the vesting of restricted shares. The shares were withheld at a price of $3.4275 per share on September 6, 2026. Following this transaction, Kenny directly holds 204,598 shares of OraSure Technologies.

Orasure Technologies Stock Price Forecast. Should You Buy OSUR?

https://stockinvest.us/stock/OSUR
StockInvest.us rates OraSure Technologies (OSUR) as a Strong Sell Candidate with a technical score of -5.19. The stock price fell by -0.88% on September 9, 2026, and has been in a falling trend, with a forecasted 17.99% fall over the next three months. The analysis indicates several negative technical signals and recommends a negative evaluation due to the weak short-term performance and lack of support.

BlackRock Inc. Takes $27.91 Million Position in OraSure Technologies, Inc. $OSUR

https://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-2791-million-position-in-orasure-technologies-inc-osur-2026-09-03/
BlackRock Inc. has acquired a new stake of 6.26 million shares in OraSure Technologies, Inc., valued at approximately $27.91 million, making them a significant shareholder with 9.09% ownership. Despite this substantial investment, analyst sentiment remains cautious with a "Reduce" consensus rating and a target price of $3.00, which is below the recent trading price of $3.61. Other institutional investors have also adjusted their positions in the medical instruments supplier, which has a market capitalization of $248.98 million and a P/E ratio of -5.23.
Advertisement

Private Management Group Inc. Cuts Stake in OraSure Technologies, Inc. $OSUR

https://www.marketbeat.com/instant-alerts/filing-private-management-group-inc-cuts-stake-in-orasure-technologies-inc-osur-2026-08-30/
Private Management Group Inc. reduced its stake in OraSure Technologies (NASDAQ:OSUR) by 30% in the second quarter, selling 1.62 million shares and retaining 3.80 million shares valued at approximately $16.9 million. Despite this, institutional investors collectively own 93.5% of OSUR's shares, with several other firms establishing new positions. OraSure Technologies, a diagnostic and medical device company, opened at $3.60, below the consensus price target of $3.00, and has a "Reduce" rating from analysts.

Cannell Capital LLC Purchases New Holdings in OraSure Technologies, Inc. $OSUR

https://www.marketbeat.com/instant-alerts/filing-cannell-capital-llc-purchases-new-holdings-in-orasure-technologies-inc-osur-2026-08-29/
Cannell Capital LLC has acquired a new position in OraSure Technologies, Inc. (NASDAQ:OSUR), purchasing over 1.4 million shares valued at approximately $6.37 million during the second quarter of 2026. This move makes OraSure Technologies the 9th largest holding for Cannell Capital, representing about 2.07% of the company. Despite significant institutional ownership (93.5%), analyst sentiment remains cautious with a "Reduce" rating and a target price of $3.00, while the stock recently traded down 2.4% at $3.60.

3,613,836 Shares in OraSure Technologies, Inc. $OSUR Acquired by Altai Capital Management L.P.

https://www.marketbeat.com/instant-alerts/filing-3613836-shares-in-orasure-technologies-inc-osur-acquired-by-altai-capital-management-lp-2026-08-25/
Altai Capital Management L.P. has acquired 3,613,836 shares of OraSure Technologies, Inc. ($OSUR), valued at approximately $16.1 million, making it their second-largest holding and representing 5.24% of the company. Institutional investors now own about 93.5% of OSUR, despite analysts maintaining a "Reduce" rating and a $3.00 price target for the stock. OraSure Technologies specializes in diagnostic and medical device products, including the OraQuick rapid HIV test.

Earnings Preview: OSUR to Report Financial Results Post-market on August 05

https://www.moomoo.com/news/post/73855225/earnings-preview-osur-to-report-financial-results-post-market-on
This article announces that OSUR is scheduled to report its financial results after the market closes on August 5th. It serves as an earnings preview, alerting investors and stakeholders to the upcoming release of the company's financial performance data.

OraSure Technologies (NASDAQ:OSUR) Gains FDA Nod for Rapid Antigen Test

https://kalkinemedia.com/us/stocks/penny/orasure-technologies-nasdaqosur-gains-fda-nod-for-rapid-antigen-test
OraSure Technologies (NASDAQ:OSUR) recently received FDA authorization for a rapid antigen test and a urine-collection sample kit, expanding its reach in at-home diagnostic testing. This development highlights the company's focus on non-invasive sampling and accessible diagnostics, positioning it well within the growing trend of decentralized healthcare. OraSure's debt-free status also provides financial resilience in a dynamic market environment.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement